St. Louis Dangerous Drug Attorneys Fighting for Injury Victims

Pharmaceutical injury cases cross multiple areas of law, requiring knowledge of both product liability principles and the specific statutes governing your claim. In Missouri, injured patients generally have five years from the date they discover their injury to file a lawsuit against a drug manufacturer under RSMo §516.120(4).

This discovery rule recognizes that many medication side effects don’t appear immediately—some complications emerge months or years after you begin taking a prescription, giving you time to connect your symptoms to the medication once you understand the link.

Illinois applies a shorter timeline, requiring most personal injury claims to be filed within two years under 735 ILCS 5/13-202. The state also has a statute of repose that references outer time limits, though its application involves fact-specific analysis requiring individual case evaluation. If you received treatment in Illinois but live in Missouri—or vice versa—additional complexity arises through borrowing statutes that may apply the shorter limitations period.

These cases differ fundamentally from medical malpractice claims because you’re pursuing product liability claims based on defective design, manufacturing flaws, or failure to provide adequate warnings.

The manufacturer’s duty to warn exists independently of your doctor’s prescribing decisions, and FDA approval doesn’t shield companies from liability when they know or should know about serious risks. As the Supreme Court confirmed in Wyeth v. Levine (2009), drug makers can strengthen warning labels without waiting for FDA permission, and federal approval doesn’t preempt state law claims for brand-name medications.

However, generic drug cases face significant obstacles under federal preemption doctrine, which means generic drug injury cases often require different legal strategies, including claims against the brand-name manufacturer or prescribing physicians. Understanding these distinctions is essential because the type of drug and your location determine both your deadline and your legal strategy.

Hidden risks not disclosed in warning labels cause thousands of preventable injuries each year. According to the CDC (2024), adverse drug events result in approximately 1.5 million emergency department visits annually nationwide, with another 500,000 hospitalizations from medication complications.

When manufacturers know about serious complications but fail to adequately warn doctors and patients, they can be held liable for resulting harm. Long-term complications from approved medications—including organ damage, cardiovascular events, and neurological injuries—may support claims even when the drug remains on the market.

Selective serotonin reuptake inhibitors (SSRIs) and other antidepressants have been linked to increased suicide risk, particularly in young adults and adolescents, while birth defects from prenatal exposure represent another serious concern with some SSRIs associated with cardiac malformations and persistent pulmonary hypertension in newborns.

These cases require careful analysis of when manufacturers knew about risks and whether warnings adequately conveyed the danger to prescribing physicians and pregnant patients.

Newer anticoagulants promised convenience over traditional blood thinners but introduced new risks, with uncontrollable bleeding events—including brain hemorrhages and gastrointestinal bleeding—causing deaths and permanent injuries.

The lack of reversal agents for some newer blood thinners meant that when bleeding began, doctors had limited options to stop it, and manufacturers’ failure to adequately warn about these risks has led to substantial litigation.

Type 2 diabetes medications, particularly certain GLP-1 agonists and DPP-4 inhibitors, have been associated with serious complications including pancreatic cancer and acute pancreatitis, while kidney failure complications from SGLT2 inhibitors represent another area of concern.

Our firm has extensive experience handling Ozempic, Mounjaro, and Wegovy lawsuits involving these newer diabetes and weight loss medications. These cases often involve questions about when manufacturers discovered the risks through post-market surveillance and whether they acted promptly to update warnings or inform the medical community.

Manufacturer deception about addiction risks fueled the opioid crisis that claimed 1,375 lives in Missouri alone during 2020, according to the Missouri Department of Health.

Pharmaceutical companies marketed opioids as safe for chronic pain while downplaying addiction potential, and some actively encouraged over-prescription practices through misleading sales tactics. These cases may involve both individual injury claims and broader public nuisance theories addressing the epidemic’s community impact.

Hormonal contraceptives carry inherent risks, but some formulations present dangers that outweigh their benefits, with blood clots and stroke risks associated with certain birth control pills causing deaths in young, otherwise healthy women.

IUD complications including uterine perforation, migration, and embedment require surgical intervention and can cause permanent reproductive harm when manufacturers fail to adequately test products or warn about known risks.

These case categories represent the most common pharmaceutical injuries we handle, but each presents unique challenges that require specialized legal expertise and courtroom experience.